Announcement • Jun 02
GE Healthcare Showcases Solutions Designed to Expand Access, Streamline Workflows and Support Precision Care Across Care Pathways
GE HealthCare showcased its latest technologies and AI-enabled workflows to help support precision care across care pathways. GE HealthCare’s Flyrcado (flurpiridaz F 18 injection) is helping expand access to PET myocardial perfusion imaging (MPI) through a ready-to-use, unit-dose model designed for routine clinical workflows. The company is also collaborating with channel partners to accelerate the adoption of cardiac PET MPI in community settings while mobile imaging models are extending access beyond traditional hospital environments, bringing precision PET imaging to sites that may not otherwise have access. GE HealthCare offers Vizamyl (flutemetamol F 18 injection) and quantitative tools such as MIMneuro to support more consistent amyloid PET interpretation and clinical decision-making. These technologies can help providers integrate amyloid imaging more efficiently into routine neurological care pathways. GE HealthCare’s StarGuide SPECT/CT, Intelligent Radiation Therapy (iRT) and MIM portfolio are designed with these needs in mind – helping simplify whole-body tumor burden assessment, streamline workflows and support more consistent treatment planning across care settings. These capabilities also support GE HealthCare’s vision for Adaptive Theranostics – a connected, data-driven approach that integrates molecular imaging, quantitative analysis and multidisciplinary workflows to help tailor therapy decisions over time. GE HealthCare’s nuclear medicine portfolio spans imaging systems, AI-enabled software and pharmaceutical diagnostics designed to help clinicians support the full patient journey — from detection and diagnosis through therapy planning and monitoring. GE HealthCare is highlighting key technologies and software designed to help healthcare systems scale precision imaging, theranostics and quantitative analysis across clinical and research settings: MIMKineticID: Advanced 510(k)-pending software designed for dynamic PET imaging and kinetic modeling, enabling quantitative, time-based analysis of radiotracer behavior to support more informed clinical and research decisions. MIM LesionID Pro: Recently 510(k) cleared by the U.S. FDA, this AI-powered software automates whole-body tumor burden analysis, reducing the need for manual lesion segmentation, physiologic uptake removal, or multi-image registration while enabling fast access to quantitative insights. Omni Legend: GE HealthCare’s fastest-selling PET/CT platform, now with more than 500 installations worldwide. Its high-sensitivity design supports faster scans, improved image quality and enhanced lesion detectability. Omni Legend also includes Precision DL deep learning image processing. StarGuide: A digital SPECT/CT platform featuring 12 CZT detectors and optimized for certain theranostic procedures, enabling high-quality 3D imaging, short scan times and quantitation. MINItrace Magni: A compact cyclotron solution designed to simplify onsite production of PET tracers and radiometals, including Gallium-68, helping expand radiopharmaceutical access and support more localized production and personalized care delivery. Flyrcado: A PET imaging agent that helps doctors evaluate myocardial ischemia and infarction in people with known or suspected coronary artery disease, including during exercise stress tests. DaTscan (ioflupane I-123 injection): A proven neurological diagnostic radiopharmaceutical – celebrating 25 years in the global market – to visualize striatal dopamine transporters assisting in the evaluation of patients with suspected Parkinsonian syndromes (PSs) and suspected dementia with Lewy bodies (DLB). Cerianna (fluoroestradiol F 18 injection): A PET radiopharmaceutical used to detect estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. Vizamyl: A PET imaging agent used to estimate amyloid beta neuritic plaque density in adults with cognitive impairment to support evaluation of Alzheimer’s disease and other causes of cognitive decline, and to help inform selection of patients for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products. These imaging technologies and agents are designed to support more scalable, data-driven and personalized nuclear medicine workflows across care pathways. Quantification and advanced imaging analytics are expected to play an increasingly important role in this evolution, particularly in neurodegenerative disease and theranostics, where more standardized interpretation and longitudinal assessment may help advance consistency across sites and clinicians. One way GE HealthCare is aiming to advance this evolution is through Adaptive Theranostics – a model that combines molecular imaging, quantitative analytics and connected clinical workflows to help clinicians personalize radioligand therapy decisions across treatment cycles. By supporting more consistent quantification, longitudinal assessment and multidisciplinary collaboration, Adaptive Theranostics is designed to help healthcare systems scale precision care as theranostics adoption grows. Cerianna (fluoroestradiol F 18 injection) is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. Cerianna is not useful for imaging other receptors such as HER2 or progesterone receptor (PR). In Clinical Trials (n=1207) the most common adverse reactions seen occurred at a rate < 1% were injection-site pain and dysgeusia. DaTscan (ioflupane I-123 injection) is indicated as an adjunct to other diagnostic evaluations for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging in adult patients with suspected Parkinsonian syndromes (PS) or suspected dementia with Lewy bodies (DLB). In clinical trials, headache, nausea, vertigo, dry mouth, or dizziness were reported at a rate of 1% or less. In postmarketing experience, hypersensitivity reactions and injection-site pain have been reported. Flyrcado (flurpiridaz F 18 injection) is a radioactive diagnostic drug indicated for PET myocardial perfusion imaging (MPI) under rest or stress in adult patients with known or suspected coronary artery disease (CAD) to evaluate myocardial ischemia and infarction. The most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence = 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.
